Additional Relevant Details Principal investigator Sandra Comer, Ph.D., Professor, Department of Psychiatry, Columbia University and New York State Psychiatric Institute (NYSPI), will present results of the completed Phase 2 trial which evaluated MN-166 (ibudilast) in patients with opioid dependence. Dr. Comer’s presentation will be held during the symposium titled, “Glial and Neuroinflammatory Modulators for Attenuating Some Abuse-Related Effects of Drugs,” at the Behavior, Biology and Chemistry Annual Meeting and Symposium.